03:41 AM EST, 11/11/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said late Monday its phase 2 study evaluating the efficacy, safety and tolerability of experimental drug, NBI-1070770, in adults with major depressive disorder did not meet the primary endpoint compared with placebo.

The drug developer said the phase 2 study enrolled 73 adult patients with a diagnosis of major depressive disorder with inadequate response to at least one antidepressant in their current episode of treatment.

Neurocrine said it acquired rights to develop and market the experimental drug from Takeda Pharmaceutical ( TAK ) .